Prolexys Pharmaceuticals yesterday announced the start of its first human trials of PRLX 93936, a potential anti-cancer compound.
Among the study centers performing the phase I studies of this erastin analog is TGen Clinical Research. At TGen and the other study sites, the safety, efficacy, and pharmocodynamic properties of PRLX 93936 will be evaluated in patients with advanced solid tumors.
"Rarely have we seen pre-clinical anti-tumor effects that match those produced by PRLX 93936," Daniel Von Hoff, the director of clinical research at TGen, and the principal investigator for the study at Scottsdale Healthcare, said in a prepared statement. "We're very hopeful that this compound will have a therapeutic effect in patients with tumors that are non-responsive to existing therapeutic agents."